Neurotransmitter transporters: Fruitful targets for CNS drug discovery

Molecular Psychiatry

Volumn 5, Issue 4, 2000, Pages 357-362

  Iversen, L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Amphetamines; Antidepressants; Cocaine; Dopamine; Neurotransmitter transporters; Norepinephrine; Serotonin; Vesicular transporters

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ADRENALIN; AMFEBUTAMONE; AMINO ACID RECEPTOR AFFECTING AGENT; AMITRIPTYLINE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CANNABINOID RECEPTOR; CELL SURFACE RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS; COCAINE; DESIPRAMINE; DOPAMINE TRANSPORTER; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MAZINDOL; MILNACIPRAN; MONOAMINE; NEUROTRANSMITTER RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; REBOXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; CARDIOTOXICITY; DEPRESSION; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; FEMALE SEXUAL DYSFUNCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW;

EID: 0033938105     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000728     Document Type: Review

References (32)

1. 3H-epinephrine and its metabolite metanephrine. J Pharmacol Exp Ther 1959; 127: 251-256.
2. 3H-norepinephrine in animals. J Pharmacol Exp Ther 1961; 132: 193-201.
3. 3 Hertting G, Axelrod J, Kopin IJ, Whitby LG. Lack of uptake of catecholamines after chronic denervation of sympathetic nerves. Nature 1961; 189: 66.
4. 4 Hertting G, Axelrod J. Fate of tritiated noradrenaline at the sympathetic nerve endings. Nature 1961; 192: 172-173.
5. 5 Iversen LL. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 1971; 41: 571-591.
6. 6 Iversen LL. Uptake processes for biogenic amines. In: Iversen L, Iversen S, Snyder S (eds). Handbook of Psychopharmacology Vol 3. Plenum Press: New York, 1975, pp 381-432.
7. 7 Masson J, Sagné C, Hamon M, El Mestikawy S. Neutrotransmitter transporters in the central nervous system. Pharmacol Rev 1999; 51: 439-464.
8. 8 Radian R, Kanner BI. Reconstitution and purification of the sodium-and chloride-coupled γ-aminobutyric acid transport glycoprotein from rat brain. J Biol Chem 1986; 260: 11859-11865.
9. 9 Pacholczyk T, Blakely RD, Amara SG. Expression cloning of an antidepressant-sensitive noradrenaline transporter. Nature 1991; 350: 350-353.
10. 10 Gründemann D, Schechinger B, Rappold GA, Schömig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nature Neurosci 1998; 1: 349-351.
11. 11 Wahle S, Stoffel W. Membrane topology of the high affinity L-glutamate transporter (GLAST-1) of the central nervous system. J Biol Chem 1996; 135: 1867-1877.
12. 12 Kavanaugh MP. Neurotransmitter transport: models in flux. Proc Natl Acad Sci US 1998; 95: 12737-12738.
13. 3H-norepinephrine by tissues. Science 1961; 133: 383.
14. 14 Healy D. The Antidepressant Era. Harvard University Press: Boston, 1998.
15. 15 Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug. Twenty years since its first publication. Life Sci 1995; 57: 411-441.
16. 16 Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283: 1305-1322.
17. 17 Chustecka Z. New challenges in the antidepressant market. SCRIP 1998; 2356: 24-25.
18. 18 Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998; 22 Suppl 1: S18-S28.
19. 19 Montgomery S. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11 Suppl 4: S9-S15.
20. 20 Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 1999; 46: 1219-1233.
21. 21 Schildkraut J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-522.
22. 22 Al-Damluji S, Kopin IJ. Functional properties of the uptake of amines in immortalised peptidergic neurones (transport-P). Br J Pharmacol 1996; 117: 111-118.
23. 23 Al-Damluji S, Kopin IJ. Binding and competitive inhibition of amine uptake at postsynaptic neurones (transport-P) by tricyclic antidepressants. Br J Pharmacol 1996; 117: 811-816.
24. 24 Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-612.
25. 25 Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B et al. Cocaine self-administration on dopamine transporter knockout mice. Nature Neurosci 1998; 1: 132-137.
26. 26 Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R et al. Cocaine reward models: conditioned place preference can be established in dopamine-and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 1998; 95: 7699-7704.
27. 27 Graul A, Castaner J. Brasofensine sulfate: antiparkinsonian dopamine reuptake inhibitor. Drugs of the Future 1999; 24: 128-132.
28. 28 Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Rehav Brain Res 1998; 94: 127-152.
29. 29 Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999; 283: 397-401.
30. 30 Cook EH, Stein MA, Krasowski MD, Cox W, Olkon DM, Kieffer JE et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995; 56: 993-998.
31. 31 Luer MS, Rhoney-Denise H. Tiagabine: a novel antiepileptic drug. Annal Pharmacother 1998; 32: 1173-1180.
32. 32 Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277: 1094-1097.